With a superstar cardiologist as its CEO, new CRISPR company targets heart disease
VERVE THERAPEUTICS
Superstar cardiologist Dr. Sekar Kathiresan is leaving Massachusetts General Hospital to run Verve, which faces scientific and financial hurdles.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario